- Home
- CLDI vs BIAF Comparison
CLDI vs BIAF Comparison
Compare CLDI & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- BIAF
- Stock Information
- Founded
- CLDI 2014
- BIAF 2014
- Country
- CLDI United States
- BIAF United States
- Employees
- CLDI N/A
- BIAF N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CLDI Health Care
- BIAF Health Care
- Exchange
- CLDI Nasdaq
- BIAF Nasdaq
- Market Cap
- CLDI 18.1M
- BIAF 14.5M
- IPO Year
- CLDI N/A
- BIAF 2022
- Fundamental
- Price
- CLDI $0.76
- BIAF $0.67
- Analyst Decision
- CLDI Strong Buy
- BIAF Strong Buy
- Analyst Count
- CLDI 3
- BIAF 1
- Target Price
- CLDI $16.67
- BIAF $6.00
- AVG Volume (30 Days)
- CLDI 1.2M
- BIAF 298.9K
- Earning Date
- CLDI 03-14-2025
- BIAF 11-14-2024
- Dividend Yield
- CLDI N/A
- BIAF N/A
- EPS Growth
- CLDI N/A
- BIAF N/A
- EPS
- CLDI N/A
- BIAF N/A
- Revenue
- CLDI N/A
- BIAF $9,367,785.00
- Revenue This Year
- CLDI N/A
- BIAF $285.51
- Revenue Next Year
- CLDI N/A
- BIAF $20.05
- P/E Ratio
- CLDI N/A
- BIAF N/A
- Revenue Growth
- CLDI N/A
- BIAF 2813.87
- 52 Week Low
- CLDI $0.69
- BIAF $0.64
- 52 Week High
- CLDI $16.80
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- CLDI 29.25
- BIAF 26.36
- Support Level
- CLDI $0.83
- BIAF $0.64
- Resistance Level
- CLDI $0.94
- BIAF $1.01
- Average True Range (ATR)
- CLDI 0.12
- BIAF 0.07
- MACD
- CLDI -0.02
- BIAF -0.01
- Stochastic Oscillator
- CLDI 9.85
- BIAF 5.99
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.